Polyaspartic acid targeted nuclide carrier, preparation method and use
By designing polyaspartic acid nanoparticle carriers, the problems of insufficient retention capacity and poor stability of radionuclides in tumor tissues in existing targeted radionuclide therapy have been solved, achieving efficient and safe targeted delivery and treatment of tumors.
Patent Information
- Application Number
- CN202410914597.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-07-09
AI Technical Summary
Current targeted radionuclide therapy faces several challenges, including the potential distribution risks of antibody drugs in non-targeted tissues, insufficient retention of small molecule and peptide drugs in tumor tissues, and non-specific leakage and poor stability of radionuclides, all of which affect the continuity and safety of treatment.
Polyaspartic acid (PAA) is used as a targeted nuclide carrier. Nanoparticles are formed through self-assembly, combining targeting and radioactive metal chelation functions. PAA nanoparticles are used to improve the efficiency and stability of nuclide delivery. PAA nanoparticles are designed to enhance targeting ability and coordination stability of radioactive metals.
It improves the efficiency of targeted tumor delivery and treatment, enhances the concentration of radionuclides in tumor tissues, reduces the risk of nonspecific leakage, maintains long-term radioactive purity and stability, and demonstrates good therapeutic effects and safety.
Smart Images

Figure CN118453920B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the research of targeted delivery for tumor treatment, and in particular to a polyaspartic acid targeted nuclide carrier, a preparation method and application thereof. Background Art
[0002] Malignant tumors are one of the major diseases that seriously endanger human health and life span. In addition to conventional surgical treatment, radionuclide therapy, which has been widely used at home and abroad, has the advantages of good efficacy, no trauma, no damage to normal tissues or slight damage, etc. It can be used to treat a variety of malignant tumors, especially those that cannot be surgically removed or cannot be completely removed or have multiple metastatic tumors, and can be used repeatedly to achieve the best therapeutic effect. Targeted radionuclide therapy (Therapeutic Radionuclide Targeting, TRT) is to deliver radionuclides or their markers to diseased tissues or cells in a targeted manner, or the diseased tissues and cells can actively take up radioactive drugs, so that radionuclides are concentrated in large quantities at the lesion site, and the irradiation dose is mainly concentrated in the lesion. The Y or β rays emitted by the decay of the radionuclide are used to produce ionizing radiation biological effects, which directly or indirectly act on biological macromolecules, such as nucleic acids and proteins, to break their chemical bonds, leading to changes in their molecular structure and function, and inhibiting or killing diseased cells to achieve the purpose of treatment. In general, normal cells and diseased cells have different sensitivities to radionuclides. The greater the cell division activity, the stronger the ability to concentrate radionuclides, the more sensitive they are to radiation, and the greater the radiation damage they suffer. While radiation destroys or inhibits diseased tissues, it causes less damage to normal tissues.
[0003] Since it is a relatively new therapy, the Therapeutic Radionuclide Targeting (TRT) system still has some shortcomings and potential risks in practical applications, such as the potential distribution risk of antibody drugs in non-targeted tissues, and the insufficient retention capacity of small molecules and peptide drugs in tumor tissues. In addition, the modification of chelators and targeting ligands may affect the coordination stability between chelators and radionuclides, thereby leading to nonspecific leakage of radioisotopes; secondly, the self-assembled polymer TRT system may accumulate nonspecifically in organs such as the liver or spleen, causing toxicity and immunogenicity risks during treatment due to its biodegradability. Moreover, the radionuclides and their markers (targeting carriers) used in the prior art usually have a relatively stable and clear correspondence, that is, the carrier and the nuclide need to be combined together when preparing radioactive targeted therapeutic drugs, and due to the radioactivity of the nuclide, strict processes, places and equipment must be in place in the relevant processes involving the nuclide, which greatly restricts the preparation and research of the targeted nuclide. In addition, the targeting of nuclear medicine requires the introduction of targeting markers. The addition of targeting markers will inevitably affect the coupling of the nuclide itself. In view of this situation, generally speaking, targeted nuclide drugs are easily lost after being injected into the body, have poor stability, and have a short effective treatment time. In addition, due to the half-life of the nuclide itself, the amount of treatment needs to be continuously increased during the course of treatment (for example, treatment is performed every day during the radiotherapy cycle) in order to improve the continuity of treatment.
[0004] Therefore, in order to improve the problems encountered by traditional radionuclide drug conjugates, such as the potential distribution risk of antibody drugs in non-targeted tissues and the insufficient retention capacity of small molecule and peptide drugs in tumor tissues, it is necessary to provide a nuclear drug targeting molecule with higher reliability and scalability. Summary of the invention
[0005] The technical purpose of the present invention is to provide a polyaspartic acid targeted nuclide carrier, a preparation method and use thereof in view of the problems existing in the background technology.
[0006] In order to achieve the above technical objectives,
[0007] The first aspect of the present invention is to provide a polyaspartic acid targeted nuclide carrier, comprising a first compound PEAR capable of self-assembly to form nanoparticles and a second compound PAL-DG, wherein the first compound PEAR has targeting properties, and the second compound PAL-DG has a radioactive metal coordination function, and the chemical structure of the first compound PEAR is shown in Formula I:
[0008]
[0009] Formula Ⅰ.
[0010] The chemical structure of the second compound PAL-DG is shown in Formula II:
[0011]
[0012] Formula II.
[0013] Preferably, in Formula I, a+b=n≈270-450, in Formula II, c+d=n≈270-450, and m≈30-100.
[0014] Preferably, the nuclide carrier has both targeting function and radioactive metal chelating function.
[0015] Preferably, in the second compound, the short peptide RGD has multiple branches in the structural formula, forming a "brush"-like structure, which can improve the chelating performance and is also beneficial for assembly with the first compound.
[0016] Preferably, in the present invention, ethylenediamine and lysine are selected for the preparation of the two compounds to perform ring-opening reaction on polyasparagine respectively, and the active amino groups thereof are used to couple functional molecules (targeting short peptide RGD, chelating agent), and the molecular weight of the polyaspartic acid targeting molecule is 2000-5000.
[0017] The second aspect of the present invention is to provide a method for preparing a polyaspartic acid targeting nuclide carrier, comprising the following steps:
[0018] (1) Synthesis of polyasparagine PSI: After aspartic acid monomer is catalyzed by phosphoric acid, N,N-dimethylformamide is added to react to obtain polyasparagine PSI;
[0019] (2) Synthesis of polyaspartic acid grafted PAL: polyaspartic acid grafted PAL is obtained by connecting the side groups with polyamino acid materials;
[0020] (3) Modification of functional groups of polyaspartic acid grafts PAL: using a chelating agent to undergo a coupling reaction with the polyaspartic acid grafts to obtain a functional molecule PAL-DG that can chelate radioactive metals;
[0021] (4) Synthesis of the targeting molecule PEAR: The ethylenediamine ring-opening product PAED is obtained by ring-opening polyasparagine with ethylenediamine, and PEAR is obtained by coupling the targeting molecule RGD;
[0022] (5) Assembly of polyaspartic acid nanoparticles.
[0023] Preferably, in step (1), the synthesis of polyasparagine PSI specifically comprises the following steps:
[0024] (1.1) 13.3 g of aspartic acid monomer was dehydrated in 5 ml of phosphoric acid at 160-180°C and vacuum pressure reduced to below 3 mmHg for 4-6 hours;
[0025] (1.2) Remove the vacuum pump and add 50-100 mL of N,N-dimethylformamide (DMF) while the mixture is still hot to fully dissolve the solids.
[0026] (1.3) The reaction solution was added dropwise into distilled water to obtain a white flake precipitate, which was filtered, washed with distilled water until neutral, and dried to obtain polyasparagine PSI;
[0027] The synthetic route is as follows:
[0028] , where n≈270~450.
[0029] Preferably, in step (2), the synthesis of polyaspartic acid graft PAL specifically comprises the following steps:
[0030] (2.1) Weigh 1.0 g of the polyasparagine PSI prepared in step (1) in three portions, dissolve it in a round-bottom flask containing a NaOH aqueous solution (5 ml, 3 mol / L), and react for 1 h in a water bath at 60 °C. Then, add a lysine aqueous solution (5 ml, 0.3 g / mL) dropwise, and continue to react for 3 h, 6 h, and 9 h at room temperature. After the reaction, adjust the system to neutral;
[0031] (2.2) The adjusted neutral system was dialyzed, frozen, and dried to obtain polyaspartic acid grafted product PAL. After molecular weight measurement, the molecular weight of the 9 h ring-opening product can meet the conditions for constructing the carrier (2000-5000), so this product was selected for subsequent reactions;
[0032] The synthetic route is as follows:
[0033] , where n=a+b≈270~450.
[0034] Preferably, in step (3), the specific steps of modifying the bifunctional chelating agent with polyaspartic acid graft PAL are as follows:
[0035] (3.1) Take 44 mg of the dried chelating agents DOTA, DOTAOH and DOTAGA (the reaction of DOTAOH and DOTAGA with PAL and the feed ratio are the same as DOTA) and dissolve them in distilled water respectively, and carry out activation reaction in the dark for 4-6 h;
[0036] (3.2) Prepare 39 mg of polyaspartic acid grafted product PAL into 1 mL of aqueous solution and add it dropwise to the reaction system. After the addition is complete, continue the reaction at room temperature in the dark.
[0037] (3.3) After the reaction is completed, the system is dialyzed, frozen, and dried to obtain chelating agent-modified polyaspartic acid grafts PAL-D, PAL-DO, and PAL-DG, respectively;
[0038] The synthetic route is as follows:
[0039] Wherein, EDC is 1-ethyl-(3-dimethylaminopropyl)carbodiimide; NHS is N-hydroxysuccinimide; TFA is trifluoroacetic acid; M represents equivalent.
[0040] Preferably, in step (4), the specific synthesis steps of synthesizing the targeting molecule PEAR are as follows:
[0041] (4.1) Dissolve 1.0 g of the polyasparagine PSI prepared in step (1) in 15 mL of N,N-dimethylformamide (DMF) and stir until completely dissolved;
[0042] (4.2) In an ice bath, maintain 4°C, slowly add 4 mL of 0.5 mL of ethylenediamine (ED) diluted with DMF, and continue the reaction for 10-30 min;
[0043] (4.3) Remove the ice bath and react at room temperature for 30-60 min;
[0044] (4.4) After the reaction is completed, the reaction solution is dialyzed against water using a dialysis bag with MWCO = 1000 Da for 48 h, and then freeze-dried to obtain white flocculent PAED;
[0045] (4.5) Dissolve the PAED prepared in the above step in distilled water, place in an ice bath, keep the system temperature below 4°C, add N-hydroxysuccinimide (NHS) activated short peptide RGD (NHS-RGD) and stir to react for 3 h;
[0046] (4.6) After the reaction is completed, the reaction solution is dialyzed against water using a dialysis bag with MWCO = 1000 Da for 24-72 hours, and then freeze-dried to obtain a white flocculent PEAR;
[0047] The synthetic route is as follows:
[0048] ;
[0049] a+b=n≈270~450, in formula Ⅱ, c+d=n≈270~450.
[0050] Preferably, in step (5), the assembly and preparation of polyaspartic acid nanoparticles specifically comprises the following steps:
[0051] (5.1) Dissolve 5 mg of PEAR obtained in step (4) in distilled water, slowly add ethanol dropwise during stirring, and then add glutaraldehyde aqueous solution GA. Add 1 μL glutaraldehyde aqueous solution for every 1 mg of PEAR, and cross-link for 4 hours.
[0052] (5.2) Remove ethanol by rotary evaporation, add distilled water to re-disperse, centrifuge, wash twice, pay attention to use ultrasonic dispersion during washing, and freeze-dry to obtain nanoparticles PEAR NPs;
[0053] (5.3) Dissolve PEAR NPs in aqueous solution, add PAL-DG, a functional molecule with a chelating agent, and continue to stir the assembly reaction at room temperature for 4-6 hours;
[0054] (5.4) The supernatant was removed by centrifugation to obtain polyaspartic acid nanoparticles PA-R&D NPs, which were stored at 4°C.
[0055] Preferably, in this aspect, the preparation method is used to prepare the polyaspartic acid targeting nuclide carrier described in the first aspect of the present invention.
[0056] The third aspect of the present invention is to provide a use of the polyaspartic acid targeted nuclide carrier according to the first aspect of the present invention, or the polyaspartic acid targeted nuclide carrier prepared according to the second aspect of the present invention as a nanonuclide carrier.
[0057] The fourth aspect of the present invention is to provide a use of the polyaspartic acid targeted nuclide carrier according to the first aspect of the present invention, or the polyaspartic acid targeted nuclide carrier prepared according to the second aspect of the present invention in tumor treatment.
[0058] The fifth aspect of the present invention is to provide a polyaspartic acid targeted nuclide carrier according to the first aspect of the present invention, or a polyaspartic acid targeted nuclide carrier prepared according to the second aspect of the present invention, and its safety use in a tumor-bearing model.
[0059] The beneficial effects of the present invention are:
[0060] (1) The present invention introduces polymer nanosystems into targeted radionuclide therapy and optimizes the tumor-targeted delivery and treatment efficiency of the Therapeutic Radionuclide Targeting (TRT) system. By designing polyaspartic acid nanoparticles, the efficiency and stability of the carried radionuclide are improved, thereby enhancing the targeting ability.
[0061] (2) The present invention obtains polyaspartic acid through a thermal polycondensation reaction. The preparation method is simple, efficient and has a high recovery rate. The polyaspartic acid graft is obtained by lysine modification. The nano-nuclide carrier obtained by the modification and screening of the present invention can carry different radioactive nuclides, has high coordination stability with the nuclides, and maintains it for a long time, which can effectively solve the problem of nonspecific leakage of radioactive isotopes.
[0062] (3) The nanosystem of the present invention has almost no killing effect on cells. The nanonuclide system carried by the nanosystem of the present invention can maintain good radioactive purity and stability at different time points, and shows good tumor targeting. The radioactive uptake in tumor tissue is significantly higher than that in normal tissue, and has good therapeutic effect and safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] Figure 1 This is the synthetic route of polyasparagine PSI in Example 1 of the present invention.
[0064] Figure 2 This is the synthesis route of the polyaspartic acid graft PAL in Example 1 of the present invention.
[0065] Figure 3 This is the synthesis route of the products PAL-D, PAL-DO and PAL-DG of the chelating agent coupled polyaspartic acid graft in Example 1 of the present invention.
[0066] Figure 4 This is the synthesis route of the targeting molecule PEAR in Example 1 of the present invention.
[0067] Figure 5 It is a simplified structural diagram of PAL-D in Example 2 of the present invention.
[0068] Figure 6 It is a simplified structural diagram of PAL-DG in Example 2 of the present invention.
[0069] Figure 7 The bifunctional chelating agent DOTAGA and Lu in Example 2 of the present invention 3+ Coordination simulation diagram.
[0070] Figure 8 The bifunctional chelating agent DOTA and Lu in Example 2 of the present invention 3+ Coordination simulation diagram.
[0071] Fig. 9 DOTA and Lu in Example 2 of the present invention 3+ IRI scatter plot of the coordination.
[0072] Fig.10 DOTAGA and Lu in Example 2 of the present invention3+ IRI scatter plot of the coordination.
[0073] Fig.11 is a TEM image of PEAR NPs in Example 2 of the present invention.
[0074] Fig.12 is a TEM image of PA-R&D NPs in Example 2 of the present invention.
[0075] Fig.13 is a Zeta potential diagram of PEAR NPs and PA-R&D NPs with different mass ratios in Example 2 of the present invention.
[0076] Fig.14 This is a graph showing the results of measuring the hydrated particle size of PEAR NPs in Example 2 of the present invention.
[0077] Fig.15 This is a graph showing the results of measuring the hydrated particle size of PA-R&D NPs in Example 2 of the present invention.
[0078] Fig.16 This is the stability test of PA-R&D NPs in Example 2 of the present invention in physiological saline and serum medium systems.
[0079] Fig.17 This is a graph showing the cytotoxicity test results of the targeted polyaspartic acid derivative PEAR on 4T1 cells in Example 3 of the present invention.
[0080] Fig.18 This is a graph showing the test results of the cytotoxicity of the chelating agent functionalized polyaspartic acid derivatives PAL-D / PAL-DO / PAL-DG on 4T1 cells in Example 3 of the present invention.
[0081] Fig.19 In Example 3 of the present invention, an inverted fluorescence microscope was used to observe the uptake comparison of PA-D NPs (nanoparticles without RGD modification) and PA-R&D NPs by 4T1 cells.
[0082] Fig. 20 This is the flow cytometric analysis of the uptake of PA-D NPs and PA-R&DNPs by 4T1 cells in Example 3 of the present invention.
[0083] Fig.21a , Figure 21b and Fig.21c They are respectively in Example 3 of the present invention [ 177 Radioactive HPLC analysis of the in vitro stability experiment of [Lu]PA-R&D NPs at 12 h, 24 h, and 48 h.
[0084] Fig. 22The 4T1 tumor-bearing mice in Example 3 of the present invention were injected with [ 68 PET / CT images at 15 min, 30 min, 1 h, 1.5 h, 3 h, and 12 h after the addition of Ga]PA-R&D NPs.
[0085] Fig.23 The 4T1 tumor-bearing mice in Example 3 of the present invention were injected with [ 177 SPECT images of Lu]PA-R&D NPs (0.2 mci) at 6h, 12h, 24h, and 48h.
[0086] Fig.24 In Example 3 of the present invention, 177 Lu] Biodistribution of PA-R&D NPs in various parts of the body of 4T1 tumor-bearing mice over time. DETAILED DESCRIPTION
[0087] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is specifically, clearly and completely described in the following embodiments in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Moreover, based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work, any modifications, equivalent substitutions, improvements, etc., should be included in the protection scope of the present invention.
[0088] In order to enable those skilled in the art to better understand the technical solution of the present invention, some technical terms of the present invention are first explained. In the text of the present invention, these explanations are mainly to help those skilled in the art understand and implement the technical solution of the present invention, rather than to limit the present invention. In addition, there may be other technical understandings of these technical terms in other disclosures outside the present invention. In order to avoid technical ambiguity, when understanding the present invention, these explanations of the present invention should be based on them.
[0089] Therapeutic Radionuclide Targeting (TRT)
[0090] Therapeutic Radionuclide Targeting (TRT) is the targeted delivery of radionuclides or their markers to diseased tissues or cells, or the active uptake of radioactive drugs by diseased tissues and cells, so that radionuclides are concentrated in large quantities at the lesion site. The irradiation dose is mainly concentrated in the lesion, and the gamma or beta rays emitted by the decay of the nuclides are used to produce ionizing radiation biological effects, which directly or indirectly act on biological macromolecules, such as nucleic acids and proteins, to break their chemical bonds, leading to changes in their molecular structure and function, and inhibiting or killing diseased cells to achieve the purpose of treatment. In general, normal cells and diseased cells have different sensitivities to radionuclides. The greater the cell division activity, the stronger the ability to concentrate radionuclides, the more sensitive to radiation, and the greater the radiation damage suffered. While the radiation destroys or inhibits the diseased tissue, the damage to normal tissue is relatively minor.
[0091] In targeted radionuclide therapy, in order to achieve effective radiolabeling, temperature, pH, and labeling reaction time are all affected by the type of chelator and need to be optimized separately. Therefore, it is a challenging task to design polyaspartate carriers according to the criteria of targeted radionuclide therapy and optimize their self-assembly, radiolabeling, pharmacokinetics, and biodistribution properties.
[0092] Polyamino Acid
[0093] Polyamino acid materials have been widely studied as drug carrier materials due to their biodegradability and low toxicity. Among them, polylysine, polyaspartic acid, polyornithine, polyglutamic acid, etc. have been studied more. Polyamino acid materials have a relatively clear molecular structure because they are obtained by dehydrating amino acid monomers to form peptide bonds. Polyamino acids can also form α-helical and β-folded structures, which are similar to natural proteins. Therefore, polyamino acids are not only biodegradable, but also can exhibit diverse functions. Polyamino acids polymerized from the same monomer are called homopolymeric amino acids. Depending on the number of carboxyl groups and amino groups of the monomeric amino acids, the homopolymeric amino acids show differences in positive and negative charges, and thus play different roles. Polyanionic amino acids such as polyglutamic acid have a molecular weight of 100-3000 KDa. The rich carboxyl groups on their surface make them have strong water retention and can also chelate a variety of ions. They have been widely used as drug carriers. Polycationic amino acids such as polylysine, because the amino groups are ionized in aqueous solution, adsorb negatively charged cell membranes through electrostatic interactions, thereby destroying the cell membrane structure and exerting a significant antibacterial effect. Various copolymers can be prepared by using two or more amino acids, or amino acids and other monomers. Polyaspartic acid has an imide ring structure, which can be opened by alkaline reagents. Therefore, various functional groups can be joined through the ring-opening reaction, which has strong modifiability, thereby adding new functions.
[0094] Thermal Polycondensation
[0095] In the synthesis of polyamino acids, the thermal polycondensation method is also called the acid-catalyzed condensation method, which allows aspartic acid monomers to undergo dehydration condensation under high temperature and low pressure conditions to obtain polyasparagine. This preparation method can easily obtain ultra-high molecular weight polyimide, but there are fewer types of polyamino acids that can be used in the subsequent process, and it is a random copolymerization.
[0096] Integrins and tumor cells
[0097] Integrins are a superfamily of cell adhesion receptors that promote cell-cell and ECM adhesion and bind to extracellular matrix ligands, cell surface ligands, and soluble ligands. v β3 is α v The heterodimer formed by the non-covalent interaction of two type I transmembrane proteins, β-adhesive protein β and β-3, is divided into three parts: intracellular domain, transmembrane domain and extracellular domain. Among them, the intracellular domain is composed of 30 to 40 amino acids, which can bind to tyrosine kinase and focal adhesion kinase to form a complex, and can participate in biological processes such as cell connection and initiation of intracellular signal cascade reactions. The transmembrane domain is the site of action of various regulatory factors and cytokines; the extracellular domain is the ligand-specific binding site. According to the type of integrin ligand, integrins can be divided into three types: laminin-binding integrins, collagen-binding integrins, and arginine-glycine-aspartic acid sequence-binding integrins. Integrins activate integrin signaling pathways by recognizing corresponding ligands, thereby regulating biological processes such as cell growth, movement, and proliferation. RGD peptides are a class of short peptides containing arginine-glycine-aspartic acid (Arg-Gly-Asp), which are widely present in the sequence of ECM proteins and can be recognized by integrins and their ligand proteins. They are widely used in tumor targeted tracing, targeted imaging and tumor diagnosis, and can also be used to monitor tumor progression and guide treatment.
[0098] Tumor cells such as primary head and neck squamous cell carcinoma, breast cancer, eyelid basal cell carcinoma, osteosarcoma, melanoma, lung cancer, prostate cancer, etc., all have integrin α v RGD peptide and its derivatives can specifically recognize and bind to integrin α on the cell membrane surface of these tumors. v β3, mediates the internalization of drugs, and is taken up by cells through the lysosomal pathway to exert its effects. v β3 has a good affinity, and when RGD is modified by coupling reaction, RGD can still maintain its affinity with integrin α v The high affinity of β3 is essential for the active targeted delivery of RGD / drug conjugates to tumor cells.
[0099] RGD peptide
[0100] Arginine-Glycine-Aspartic Acid (Arg-Gly-Asp)-containing short peptide
[0101] Chelating agents
[0102] Metal atoms or ions react with ligands containing two or more coordinating atoms to form a complex with a ring structure, which is called a chelate. The ligand substance that can form a chelate is called a chelating agent, also known as a complexing agent. It is also called a chelating ligand, a chelating group or a mutidentate ligand.
[0103] The bifunctional chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracarboxylic acid (DOTA for short) mentioned in the embodiments of the present invention is a twelve-membered tetraazamacrocyclic ligand, which is essentially a product in which the hydrogens on the four nitrogens in the cycloamine are replaced by acetic acid groups. When the substance was discovered, it was proven to form stable chelates with metal ions and was widely used to label nuclides to achieve the purpose of tumor diagnosis and treatment. The improved derivatives of the ligand can be used as bifunctional chelating agents. DOTAGA is a type of DOTA derivative. The substance has a glutaric acid side group and can be used to couple larger molecular weights, improve system stability, and reduce the impact on chelated metal ions.
[0104] Example 1, establishment of a nano-nuclide carrying system.
[0105] The preparation method of the polyaspartic acid nanonuclide carrier provided in this embodiment specifically comprises the following steps:
[0106] (1) Synthesis of polyasparagine (PSI): 13.3 g of aspartic acid monomer was reacted at 160-180°C and vacuum pressure reduced to below 3 mmHg for 4 hours under the catalysis of 5 mL of phosphoric acid. The vacuum pump was removed and 50 mL of N,N-dimethylformamide (DMF) was added while hot to fully dissolve the solid. The reaction solution was added dropwise into distilled water to obtain a white flaky precipitate. The precipitate was filtered, washed with distilled water until neutral, and dried to obtain polyasparagine PSI. The synthetic route is as follows: Figure 1 shown.
[0107] (2) Lysine ring-opening PSI to obtain polyaspartic acid grafted product (PAL): Weigh three portions of 1.0 g PSI and dissolve them in a round-bottom flask filled with a NaOH aqueous solution (5 mL, 3 mol / L). Keep the system at 60°C in a water bath for 1 h. Add 5 mL of an aqueous solution prepared with 1.5 g lysine dropwise and continue the reaction for 3 h, 6 h, and 9 h. After the reaction, adjust the system to neutral. The system is dialyzed, frozen, and dried to obtain polyaspartic acid grafted product PAL. Its synthetic route is as follows: Figure 2 shown.
[0108] Through the above steps, the water solubility of the polyaspartic acid precursor is improved, more reactive sites are introduced, and a copolymer PAL with a suitable molecular weight is selected to facilitate subsequent functional modification.
[0109] (3) Modification of functional groups of PAL: 44 mg of dry bifunctional chelator DOTA (the reaction and feed ratio of DOTAOH, DOTAGA and PAL are the same as those of DOTA) was dissolved in distilled water, activated with 59.1 mg EDCI and 34.5 mg NHS in the dark for 3 h, and then 39 mg PAL was added. The reaction was continued in the dark at room temperature overnight. After the reaction, the system was dialyzed, frozen, and dried to obtain the products of chelator-modified PAL (PAL-D, PAL-DO, PAL-DG). The synthetic route is as follows: Figure 3 shown.
[0110] (4) Synthesis of targeting molecule (PEAR): Dissolve 1.0 g PSI in 15 mL DMF, stir until completely dissolved, then place in an ice bath, maintain at 4°C, slowly drop 4 mL of 0.5 mL ethylenediamine (ED) diluted with DMF, continue the reaction for 10-30 min, then remove the ice bath and react at room temperature for 30-60 min. After the reaction is completed, dialyze the reaction solution against water using a dialysis bag (MWCO=1000 Da) for 48 h, and then freeze-dry to obtain a white floc (PAED). Dissolve the above PAED in distilled water, place in an ice bath, maintain the system temperature below 4°C, add short peptide RGD (NHS-RGD) activated by N-hydroxysuccinimide (NHS), and stir to react for 3 h. After the reaction is completed, dialyze the reaction solution against water using a dialysis bag MWCO=1000 Da for 48 h, and then freeze-dry to obtain a white floc PEAR; its synthesis route is as follows Figure 4 shown.
[0111] (5) Preparation of polyaspartic acid nanoparticles: 5 mg of PEAR was dissolved in distilled water, stirred, and ethanol was slowly added to the PEAR solution, followed by addition of 170 μL of 8% (v / v) glutaraldehyde aqueous solution for cross-linking for 4 h. The ethanol was removed by rotary evaporation, and the mixture was redispersed with distilled water, centrifuged, washed twice, dispersed by ultrasound, and freeze-dried to obtain nanoparticles PEAR NPs. PEAR NPs were dissolved in aqueous solution, and 25 mg of a functional molecule with a chelating agent (PAL-DG) (whose chemical structure is shown in Formula I) was added. The assembly reaction was continued for 3 h, and the supernatant was removed by centrifugation to obtain polyaspartic acid nanoparticles PA-R&D NPs, which were stored at 4°C.
[0112] In this example, a functional moiety PAL-DG with a high labeling rate for lutetium ions and a targeting moiety PEAR were synthesized and screened, and self-assembled to form nanoparticles PA-R&D NPs, which can be recognized by integrin receptors, thereby precisely delivering the nuclide to the tumor site.
[0113] PA-R&D NPs use polyaspartic acid as the skeleton. Compared with traditional polymer materials, they have a higher 177Lu labeling rate and can remain stable for a longer period of time, which broadens the application of polyamino acid materials in the field of radionuclide therapy.
[0114] Example 2, stability verification.
[0115] This example discusses the coordination stability of the precursor polyaspartic acid conjugate with gallium trivalent ions and lutetium trivalent ions. The coordination stability with lutetium trivalent ions was studied in detail through theoretical calculations. Polyaspartic acid (PAL-DG) coupled with a bifunctional chelator was obtained through screening. Finally, a targeting integrin α v Polyaspartic acid nanoparticle carriers (PA-R&D NPs) of β3 were prepared and characterized.
[0116] The specific analysis and verification process is as follows:
[0117] For ligands (PAL-D, PAL-DG) and ions Lu 3+ The interaction force between them was analyzed by the interaction region indicator function (IRI), which is essentially the norm of the weighted electron density gradient divided by the scaled electron density and is expressed as:
[0118] IRI(r)= | ∇ ρ(r)| [ρ(r)] α
[0119] Among them, ρ represents the electron density; r represents the coordinate vector.
[0120] First, simplify the PAL-D and PAL-DG structures as follows: Figure 5 and Figure 6 , these structures retain the same 3+ Functional groups that form coordination bonds, and DOTA and DOTAGA with Lu 3+ The coordination effect of Figure 7 and Figure 8 As shown, Figure 7 and Figure 8 The green areas shown in the figure represent the van der Waals region, red represents steric hindrance, and blue represents attractive forces. The blue isosurfaces represent stronger weak interactions or chemical bonds. For PAL-DG, Lu 3+ The isosurfaces between O, N, and O in H2O are dark blue, and there are 9 such isosurfaces, indicating that Lu3+ is chelated with PAL-DG in a 9-coordinated form. For PAL-D, there are only 8 such isosurfaces, indicating that Lu 3+ It exists in an 8-coordinated form. This is because the O on one of the carboxyl groups in PAL-D is replaced by N, and the O on the carboxyl group does not interact with Lu 3+ Instead of forming coordination bonds, they exhibit weak interactions. The IRI scatter plot of PAL-DG ( Fig.10 ) shows that sign(λ2)ρ is mainly distributed in the range of -0.07 to -0.02 atomic units, corresponding to Lu 3+ and PAL-DG. In contrast, the IRI scatter plot of PAL-D ( Fig. 9 ) shows some sharp peaks between -0.01 and 0.0, corresponding to Lu 3+ Therefore, we conclude that PAL-DG is better able to interact with Lu 3+ Coordination forms a more stable structure.
[0121] Through the above experiments, polyaspartic acid (PAL-DG) with good stability coupled with bifunctional chelating agents was screened and the targeting integrin α was constructed. v The polyaspartic acid nanoparticle carrier (PA-R&D NPs) of β3 was selected with a mass ratio of PAL-DG: PEAR NPs = 2:1. The system was characterized by TEM images, Zeta points and hydrated particle size determination. The characterization results are as follows: Figure 11-Figure 15 As shown, the particle size measurement result is about 210 nanometers, and the particle size is uniform; the surface charge of the system is -18.6mV, the surface charge is moderate, the morphology is regular, and it can remain stable for a long time.
[0122] The stability of PA-R&D NPs was tested in saline and serum medium. Fig.16 As shown, the results showed that the system showed good stability in 1640 medium containing 10% serum.
[0123] Example 3, safety verification.
[0124] This example demonstrates the cytotoxic effect and cell internalization performance of PA-R&D NPs through experiments.
[0125] (1) If Fig.17 and Fig.18 The figures show the test results of cytotoxicity (MTT method, mean±SD, n=5) of targeted polyaspartic acid derivative PEAR and chelating agent functionalized polyaspartic acid derivative PAL-D / PAL-DO / PAL-DG on 4T1 cells. The results show that the nanosystem has almost no killing effect on cells and can be effectively taken up by 4T1 cells.
[0126] (2) The uptake of PA-D NPs (unmodified RGD nanoparticles) and PA-R&D NPs by 4T1 cells was observed using an inverted fluorescence microscope (scale bar: 50 µm). Fig.19 As shown; the uptake of PA-D NPs and PA-R&D NPs by 4T1 cells was analyzed by flow cytometry, and the results are shown Fig. 20 As shown in the figure, it can be seen that the nanosystem showed higher uptake compared to PA-D NPs without RGD.
[0127] (3) By marking 177 Lu got 177 Lu]PA-R&D NPs, the results were evaluated by radio-high performance liquid chromatography (Radio-HPLC). As shown in Figure 21, at different time points (12 hours, 24 hours, and 48 hours), the system maintained good radiochemical purity and stability.
[0128] (4) The distribution of nanoparticles in 4T1 tumor-bearing nude mice was monitored in real time by small animal positron emission tomography / computed tomography (micro-PET / CT) and single photon emission computed tomography (SPECT) imaging techniques. The PET / CT images of [68Ga]PA-R&D NPs uptake in the tumor confirmed the integrin-mediated radiotracer uptake. [68Ga]PA-R&D NPs (150 μCi) were injected into the tail vein of 4T1 tumor-bearing mice, and images were acquired at 15 min, 30 min, 1 h, 1.5 h, 3 h, and 12 h after [68Ga]PA-R&D NPs injection. The results are shown in Figure 4. Fig. 22 PET / CT showed that the system showed good tumor targeting, and the radioactive uptake of tumor tissue was significantly higher than that of normal tissue. 177Lu]PA-R&D NPs (0.2 mci) were injected into 4T1 nude mice (n = 2) and SPECT imaging was performed at 6 h, 12 h, 24 h, and 48 h. Fig.23 As shown, SPECT imaging results further confirmed the accumulation of NPs in tumor tissues, which peaked within 24 h after injection.
[0129] (5) Biodistribution study was performed by injecting [ 177 Lu]PA-R&D NPs, and tissue samples were collected at different time points. The results of γ-counter measurement showed that the tumor had a high radioactive uptake. Fig.24 As shown in the figure, it can be seen that within a certain period of time, except for the targeted site, there is no [ 177 Lu]PA-R&D NPs or the content is very low, while for the targeted site, [ 177 Lu]PA-R&D NPs can maintain a high content within 48 hours. Combined with the in vivo anti-tumor efficacy evaluation, [ 177 Lu]PA-R&D NPs have a killing effect on tumor cells in nude mice, indicating that they have potential therapeutic effects. 177 Lu]PA-R&D NPs did not cause damage to normal tissues of mice, demonstrating their safety in tumor-bearing models.
[0130] Although the preferred embodiments of the present invention have been described in the specification, once the basic creative concept is known to those skilled in the art, they may make additional changes and modifications to these embodiments or combinations of embodiments without creative work. Therefore, the protection scope of the present invention should be understood as the scope that the claims are intended to explain and cover, and should not be limited to the parts described in detail in the specification and embodiments of the present invention, and the contents described in the present invention, including the preferred embodiments, include all changes and modifications that fall within the scope of the present invention.
Claims
1. A polyaspartic acid targeting nuclide carrier, Features: The invention comprises a first compound PEAR capable of self-assembly to form nanoparticles and a second compound PAL-DG, wherein the first compound PEAR has targeting property, and the second compound PAL-DG has radioactive metal coordination function, and the chemical structure of the first compound PEAR is shown in Formula I, and the chemical structure of the second compound PAL-DG is shown in Formula II: Formula I; Formula II; In formula I, a+b≈270~450, in formula II, c+d≈270~450, m≈30~100.
2. A polyaspartic acid targeting nuclide carrier according to claim 1, Features: Ethylenediamine and lysine are selected to carry out ring-opening reaction on polyasparagine respectively, and the active amino groups thereof are used to couple functional molecules. The molecular weight of the nuclide carrier is 2000-5000.
3. A polyaspartic acid targeting nuclide carrier according to claim 1, Features: The nuclide carrier has both targeting function and radioactive metal chelating function.
4. A method for preparing a polyaspartic acid targeting nuclide carrier, Features: It is configured to be used for preparing the nuclide carrier according to any one of claims 1 to 3, and comprises the following steps: (1) Synthesis of polyasparagine PSI: Aspartic acid monomer reacts with phosphoric acid as a catalyst to obtain polyasparagine PSI; (2) Synthesis of polyaspartic acid grafted compound PAL: polyaspartic acid grafted compound PAL is obtained by ring-opening reaction of polyasparagine PSI with lysine; (3) Modification of functional groups of polyaspartic acid grafted material PAL: using a chelating agent to undergo a coupling reaction with polyaspartic acid grafted material PAL to obtain a functional molecule PAL-DG that can coordinate radioactive metals; (4) Synthesis of the targeting molecule PEAR; the ethylenediamine ring-opening product PAED was obtained by ring-opening of polyasparagine PSI with ethylenediamine, and PEAR was obtained by coupling with the targeting molecule RGD; (5) Assembly of polyaspartic acid nanoparticles.
5. A method for preparing a polyaspartic acid targeting nuclide carrier according to claim 4, It is characterized in that In step (1), the synthesis of polyasparagine PSI specifically includes the following steps: (1.1) Aspartic acid monomer is dehydrated under phosphoric acid catalysis at 160-180°C and vacuum pressure reduced to below 3 mmHg for 2-3 hours; (1.2) Remove the vacuum pump and add 50-100 mL of N,N-dimethylformamide (DMF) while the mixture is still hot to fully dissolve the solids. (1.3) The reaction solution was added dropwise into distilled water to obtain a white flake precipitate, which was filtered, washed with distilled water until neutral, and dried to obtain polyasparagine PSI; The synthesis route is as follows: 。 6. The method for preparing a polyaspartic acid targeting nuclide carrier according to claim 4, It is characterized in that In step (2), the synthesis of polyaspartic acid grafted material PAL specifically includes the following steps: (2.1) Weigh three equal portions of the polyasparagine PSI prepared in step (1), dissolve them in a round-bottom flask filled with a NaOH aqueous solution, and react for 1 h in a water bath at 60°C. Then, dropwise add a lysine aqueous solution and continue the reaction for 3 h, 6 h, and 9 h, respectively. After the reaction is completed, adjust the system to neutral; (2.2) The adjusted neutral system is dialyzed, frozen, and dried to obtain polyaspartic acid grafted product PAL; the ring-opening product after 9 hours is selected for subsequent reaction; The synthesis route is as follows: 。 7. The method for preparing a polyaspartic acid targeting nuclide carrier according to claim 4, It is characterized in that In step (3), the specific steps of modifying the bifunctional chelating agent with polyaspartic acid graft PAL are as follows: (3.1) Dissolve the chelating agent DOTAGA in distilled water and perform activation reaction in the dark for 4-6 hours; (3.2) Prepare polyaspartic acid grafted product PAL into an aqueous solution, add it dropwise into the reaction system, and continue the reaction at room temperature in the dark after the addition; (3.3) After the reaction is completed, the system is dialyzed, frozen, and dried to obtain the chelating agent-modified polyaspartic acid grafted product PAL-DG; The synthetic route is as follows: 。 8. The method for preparing a polyaspartic acid targeting nuclide carrier according to claim 4, It is characterized in that In step (4), the specific synthesis steps of the targeting molecule PEAR are as follows: (4.1) Dissolve the polyasparagine PSI prepared in step (1) in N,N-dimethylformamide DMF and stir until completely dissolved; (4.2) Place in an ice bath, keep below 4°C, and slowly and dropwise add ethylenediamine (ED) diluted with DMF, and continue the reaction for 10-30 min. (4.3) Remove the ice bath and react at room temperature for 30-60 min; (4.4) After the reaction is completed, the reaction solution is dialyzed against water using a dialysis bag with MWCO = 1000 Da for 48 h, and then freeze-dried to obtain white flocculent PAED; (4.5) Dissolve the PAED prepared in the above step in distilled water, place in an ice bath, keep the system temperature below 4°C, add the short peptide RGD activated by N-hydroxysuccinimide (NHS), i.e., NHS-RGD, and stir to react for 3 h; (4.6) After the reaction is completed, the reaction solution is dialyzed against water using a dialysis bag with MWCO = 1000 Da for 24-72 hours, and then freeze-dried to obtain a white flocculent PEAR; its synthesis route is as follows: 。 9. The method for preparing a polyaspartic acid targeting nuclide carrier according to claim 4, It is characterized in that In step (5), the assembly and preparation of polyaspartic acid nanoparticles specifically includes the following steps: (5.1) Dissolve the PEAR prepared in step (4) in distilled water, slowly add ethanol dropwise during stirring, and then add glutaraldehyde aqueous solution GA at a ratio of 1 mg PEAR to 1 μL glutaraldehyde aqueous solution, and cross-link for 4 h; (5.2) Remove ethanol by rotary evaporation, add distilled water to re-disperse, centrifuge, wash twice, pay attention to use ultrasonic dispersion during washing, and freeze-dry to obtain nanoparticles PEAR NPs; (5.3) Dissolve PEAR NPs in aqueous solution, add PAL-DG, a functional molecule with a chelating agent, and continue to stir the assembly reaction at room temperature for 4-6 hours; (5.4) The supernatant was removed by centrifugation to obtain polyaspartic acid nanoparticles PA-R&D NPs, which were stored at 4°C.
